Cytokine profile in multiple myeloma.

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Cytokines are critical for the progression of multiple myeloma (MM).
• Key cytokines implicated include Vascular Endothelial Growth Factor (VEGF), Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF-α), B-cell activating factor (BAFF), and Receptor Activator of Nuclear Factor-κB ligand (RANKL).

Purpose of the Study:

• To measure serum concentrations of five key cytokines in newly diagnosed and relapsed/refractory multiple myeloma (RRMM) patients.
• To investigate the correlation of these cytokine levels with disease status and patient survival.

Main Methods:

• Serum cytokine levels (VEGF, IL-6, TNF-α, BAFF, RANKL) were measured in 68 newly diagnosed and 21 RRMM patients.
• Cytokine concentrations were compared between patient groups and with healthy controls.
• Survival analysis (progression-free survival and overall survival) was performed in relation to cytokine levels and clinical parameters.

Main Results:

• Median serum levels of VEGF, IL-6, BAFF, and RANKL were higher in RRMM patients compared to newly diagnosed patients, with a significant difference in BAFF (p=0.04).
• Newly diagnosed and RRMM patients exhibited significantly higher levels of all five cytokines compared to controls.
• Serum cytokine levels decreased significantly after treatment in responders, and IL-6 levels differed significantly between patients who died and those who survived.

Conclusions:

• Serum levels of VEGF, IL-6, TNF, BAFF, and RANKL are elevated in multiple myeloma and decrease post-treatment.
• Circulating cytokine concentrations may reflect bone marrow levels and can potentially be used for monitoring disease status and treatment efficacy.